Posted by Michael Wonder on 25 Jul 2022
TGA provisionally approves the Biocelect (Novavax) COVID-19 vaccine, Nuvaxovid, for use in individuals aged 12-17 years
25 July 2022 - The TGA has provisionally approved the Biocelect (on behalf of Novavax) COVID-19 vaccine, Nuvaxovid, for use in individuals aged 12-17 years.
The decision follows provisional approvals on 19 January 2022 for the use of Nuvaxovid in adults, on 9 June 2022 the Nuvaovid booster dose for use in adults.
